LYTGOBI est le premier inhibiteur du FGFR à liaison irréversible dans l’Union européenne pour le traitement des patients atteints de cholangiocarcinome ZUG, Suisse, 4 juillet 2023 /PRNewswire/ — Taiho Oncology Europe GmbH et Taiho Pharmaceutical Co., Ltd. ont annoncé aujourd’hui que la…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.